News & Insights

Vir Biotechnology announces its underwritten public offering of 20,294,117 shares of common stock at $8.50 per share, including the exercise in full of the underwriters’ option to purchase additional shares.

Gunderson Dettmer represented long-time client BillionToOne, Inc. (Nasdaq: BLLN), a molecular diagnostics company on a mission to make powerful and accessible genetic tests available to all, in its initial public offering of 4.6 million shares of Class A common stock at a price to the public of $60 per share, generating approximately $273.1 billion in aggregate gross proceeds.

Aeva Technologies, a leader in next-generation sensing and perception systems, announces Apollo’s purchase of $100 million in aggregate principal amount of 4.375% convertible senior notes due 2032.